A new market research report published in late June by HTF market Intelligence Consulting, suggests that the Antibody-drug conjugates (ADC) Market in China is expected to grow exponentially.
The study forecast growth to 2022 and presents an in-depth strategic assessment of the antibody-drug conjugates, highlighting a number of influencing factors impacting or reinforcing market environment, including government policy, technological changes along with market drivers.
Growing footprint
One of the key markets covered by the authors of the report is China and highlights the growth in China, the increased, and growing, manufacturing base and geographic footprint. Finally, the report strategically profiles key players in the market and comprehensively analyze their growth strategies.
With a population of 1.4 billion (2017) and a rapidly expanding economy, China has become a manufacturing powerhouse. In addition, China is pursuing a goal of becoming a major hub for international bio-pharmaceutical product research, development and manufacturing. In realizing the first steps in this ambitious goal, China has, over the past decade, become a major destination for the global pharmaceutical industry to conduct R&D activities.[1]
The study, which entirely focuses on antibody-drug conjugates, considers key data such as (current) revenue, market size, expected growth, and price from all major biotechnology and pharmaceutical companies operating in China.
